What Kataval Treats: Main Uses and Benefits

The combination is applied across domains where additional symptomatic support is needed, focusing on skin conditions that involve both inflammation and bacterial presence. This combination is commonly used when short-term symptomatic assistance is needed in contexts involving heightened systemic burden. The medication is generally used to reduce itching, redness, and inflammation associated with various dermatoses.

Management of Infected Corticosteroid-Responsive Dermatoses

The medication is commonly used across conditions presenting with acute episodes, such as certain forms of eczema and dermatitis (e.g., atopic or contact dermatitis), when lesions are characterized by bacterial contamination. This therapeutic focus supports the patient by addressing the symptoms related to inflammatory states and helping to ease the disruption caused by microbial presence.

Rapid Symptomatic Relief of Acute Skin Distress

Kataval is applied during phases when symptoms become more noticeable to provide symptomatic relief. It helps address symptom clusters that may become intense or disruptive, such as pruritus (itching), redness (erythema), and swelling (edema). This supportive action contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.

“This supportive action contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.”

The medication is relevant for easing symptoms related to inflammatory or irritative states that have been complicated by secondary infection.

Quick Fact: Relief for Pruritus
Pruritus (intense itching) is a key symptom this combination is applied to manage, helping to interrupt the itch-scratch cycle common in infected skin conditions.

Regulatory References

1. Triamcinolone Topical: MedlinePlus Drug Information

Who can and cannot use Kataval?

This section outlines the official, regulator-defined eligibility criteria for using Kataval (Neomycin and Triamcinolone Acetonide combination), based strictly on government-approved prescribing information.

Contraindicated Populations (Absolute Non-Eligibility)

Use of Kataval is formally prohibited in the following groups, as stated in regulatory labels:

• Patients with Known Hypersensitivity: Individuals with documented allergies to Neomycin, Triamcinolone Acetonide, or any other component of the formulation.
• Patients with Non-Bacterial Skin Infections: Contraindicated in the presence of primary skin conditions caused by viruses (e.g., herpes simplex), fungi, or Tuberculosis (TB).
• Patients with Perforated Eardrum: Prohibited for use in the external ear canal when the eardrum is compromised.

Populations Requiring Conditional Use

Specific populations require limited or monitored use due to risks outlined in official labeling:

Population/Condition	Restriction or Condition for Use
Pediatric Patients (Children/Infants)	Use must be minimized and closely monitored due to the higher risk of systemic corticosteroid absorption and HPA axis suppression. Not recommended for children under two years.
Pregnancy/Lactation	Caution is advised. Use is permitted only if the potential benefit justifies the potential risk.
Impaired Renal Function	Caution is advised due to the risk of Neomycin-related nephrotoxicity or ototoxicity if systemic absorption is increased.

Eligibility is also restricted for application to large surface areas or under occlusive dressings, as these methods increase systemic absorption beyond labeled limits.

Interactions with Other Medicines and Products

The interaction profile of Kataval, a combination product containing Triamcinolone Acetonide and Neomycin, is documented based on the systemic potential of its active components, particularly when absorbed through the skin.

Pharmacokinetic and Pharmacodynamic Interactions

The corticosteroid component, Triamcinolone, is subject to interactions that alter its systemic exposure. Co-administration with strong CYP3A4 inhibitors (such as certain antiviral and antifungal agents) may increase systemic corticosteroid levels by inhibiting its metabolism. Conversely, drugs classified as hepatic enzyme inducers (suchg as rifampin or phenytoin) may reduce corticosteroid levels by accelerating its clearance.

Interaction Type	Interacting Substances/Products
Exposure-Altering	Strong CYP3A4 Inhibitors, Hepatic Enzyme Inducers, Grapefruit/Grapefruit Juice
Additive Risk	Other Corticosteroid-Containing Products, Systemic Aminoglycoside Antibiotics

Contraindicated Combinations

Certain combinations are classified as restricted or contraindicated based on regulatory documents for the active ingredients. This includes the co-administration of live or live attenuated vaccines when the corticosteroid is used in doses that may cause immunosuppression. Additionally, using Kataval concurrently with other systemic aminoglycoside antibiotics is cautioned against due to the potential for an additive risk of serious effects such as ototoxicity and nephrotoxicity from the Neomycin component.

Population and Food-Related Notes

While specific dosing separation rules are not documented for this topical preparation, the consumption of grapefruit or its juice is noted to potentially increase systemic corticosteroid exposure. Regulatory labeling also notes that children are more susceptible to systemic effects from the corticosteroid, which can heighten the risk associated with exposure-altering interactions.

How Kataval Works

---

Kataval functions as a small molecule inhibitor of the Glycogen Synthase Kinase-3 beta (GSK-3 beta) protein. Kataval establishes competitive inhibition by binding to the ATP-binding pocket of GSK-3 beta. This interaction prevents the phosphorylation of the enzyme's specific target substrates, including the key regulator Dishevelled.

The decreased phosphorylation of Dishevelled initiates a central modulation of the canonical Wnt/ beta-catenin signaling pathway. This regulatory event prevents the proteasomal destruction of beta-catenin within the cytosol, facilitating its subsequent nuclear translocation. In the nucleus, beta-catenin acts as a transcriptional coactivator, altering the expression of target genes involved in bone remodeling.

This intracellular cascade ultimately modulates the differentiation, proliferation, and activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). The resulting system-level physiological modulation influences calcium homeostasis and bone matrix turnover.

Kataval (ketamine hydrochloride) is a sterile solution administered solely by healthcare professionals and must be used strictly according to government-verified regulations.

Official Administration and Dosage

Kataval is administered either as an intravenous (IV) injection into a vein or an intramuscular (IM) injection into a muscle. The dosage must be individualized and titrated to achieve the necessary clinical effect.

Administration Route	Initial Dose Range (Induction)	Administration Rate
Intravenous (IV)	1 mg/kg to 4.5 mg/kg	Slowly, over a period of 60 seconds
Intramuscular (IM)	6.5 mg/kg to 13 mg/kg	---

For IV maintenance, additional increments (one-half to the full induction dose) may be administered as needed, or the medicine may be given via a slow IV microdrip infusion at a rate of 0.1 to 0.5 mg/minute in adult patients.

Preparation and Procedural Rules

Dilution is mandatory for the most concentrated 100 mg/mL formulation before it can be injected into a vein; it must be diluted with an equal volume of 0.9% Sodium Chloride Injection or 5% Dextrose in Water. Any diluted product must be used immediately.

The medicine must be administered by, or under the direction of, physicians experienced in general anesthetics. Continuous monitoring of the patient's vital signs is required, and emergency airway equipment must be readily available. The effect of a single IV induction dose typically lasts 5 to 10 minutes, while an IM dose lasts 12 to 25 minutes, which dictates the need for maintenance doses for longer procedures.

Research Evidence / Overview of Studies for Kataval

Evidence for Use in Infected Corticosteroid-Responsive Dermatoses

The combination of the corticosteroid Triamcinolone Acetonide and the antibiotic Neomycin was studied in the context of conditions characterized by fluctuating or episodic manifestations, such as certain forms of eczema that have concurrent bacterial presence. Research focused on episodes where symptoms become more noticeable, which was associated with concurrent bacterial presence.

The evidence base includes short-term Randomized Controlled Trials (RCTs). Researchers examined outcomes related to physical discomfort and inflammatory or irritative states. They used specific measurement scales to track changes in overall disease severity and symptom intensity over defined time intervals. Findings describe patterns observed in the studies that used the dual-component product in comparison with other trial comparators in populations with these complex skin conditions.

Comparison of Combination Therapy vs. Corticosteroid Alone

Research has explored the inclusion of the anti-infective component, Neomycin, with the anti-inflammatory component, Triamcinolone Acetonide. This was evaluated in studies comparing the full combination to trial arms involving the corticosteroid component alone in conditions where bacterial presence may be a complicating factor.

Data indicate patterns related to symptom evolution when the anti-inflammatory and anti-infective agents are studied together. The goal of this research was studied for how the dual-action approach contributes to outcomes during episodes where symptoms become more noticeable.

Long-Term Studies and Follow-up Duration

Most clinical studies for this combination product were conducted during periods of increased symptom activity and were of limited duration. The typical follow-up durations were limited, usually ranging from seven to 28 days.

As a result, there is limited information for long-term outcomes when applying Kataval. The existing research provides insight into short-term changes and how symptoms evolved in the observed populations during the initial treatment window. However, the effects beyond this short interval, such as outcomes related to longer-term management of the skin condition, are not fully established by the existing research landscape.

Key Studies & References

1. Summary of Evidence - Topical Antibiotics for Infected Dermatitis: A Review of the Clinical Effectiveness and Guidelines
2. Topical corticosteroids - Systematic review of treatments for atopic eczema

Common questions about Kataval (FAQ)

Q: What is the active ingredient in Kataval?

According to the official product information, the active substance in Kataval is diclofenac epolamine. This compound is the primary component responsible for the medicine's intended effect.

Q: What kind of pain is Kataval used to treat?

Regulatory documents state that Kataval is indicated for the short-term treatment of mild to moderately severe acute pain. This typically includes pain that has an immediate onset, such as pain following injuries, dental procedures, or acute musculoskeletal issues.

Q: How quickly does Kataval start to work?

Studies and official information indicate that Kataval has a rapid onset of action. Regulatory information indicates the formulation is designed for quick absorption, which contributes to its quick onset of action.

Q: Does Kataval contain any substances I might need to be aware of if I have allergies?

Official product information lists ingredients beyond the active substance. These can include aspartame and potassium. Patients with specific sensitivities or allergies to these components are typically advised to review the full list of ingredients in the official leaflet.

Q: Can I take Kataval with food?

According to official information, Kataval is generally taken on an empty stomach. Taking it this way aligns with instructions intended to support the medicine's fast-acting characteristics for optimal pain relief.

Q: If I miss a dose of Kataval, what should I do?

Official instructions for missed doses are designed to prevent taking too much medicine. General regulatory guidance states that missed doses should not be doubled up. Detailed, individual directions on what to do when a dose is missed are found in the 'How to Use' section of the full product information.

Q: What should I do if I accidentally take too much Kataval (overdose)?

Regulatory information specifies that contacting a doctor or the nearest hospital emergency department is necessary if more Kataval than prescribed is taken. It is often advised to have the medicine packaging available for reference. Signs of taking too much can include symptoms such as nausea, abdominal discomfort, or dizziness.

The official regulatory requirements for storing Kataval, a semi-solid topical combination, are defined by strict temperature and stability rules.

Storage Conditions

Requirement	Official Rule
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Freezing/Stability	Avoid freezing the product, as this can compromise its stability.
Container	Keep the container tightly closed to protect integrity and keep it out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Kataval must adhere to official guidelines to prevent environmental contamination and misuse.

The preferred method is to utilize community drug take-back programs or authorized collection sites. If these are unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before being thrown into household trash. Consumers must scratch out all identifying information from the label before discarding the container.